Merck KGaA
XETRA:MRK
Intrinsic Value
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. [ Read More ]
The intrinsic value of one MRK stock under the Base Case scenario is 146.43 EUR. Compared to the current market price of 146.75 EUR, Merck KGaA is Fairly Valued.
Valuation Backtest
Merck KGaA
Run backtest to discover the historical profit from buying and selling MRK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Merck KGaA
Current Assets | 12.4B |
Cash & Short-Term Investments | 2.5B |
Receivables | 4.6B |
Other Current Assets | 5.3B |
Non-Current Assets | 36.1B |
Long-Term Investments | 984m |
PP&E | 9.1B |
Intangibles | 24.4B |
Other Non-Current Assets | 1.7B |
Current Liabilities | 8.7B |
Accounts Payable | 2.5B |
Accrued Liabilities | 83m |
Other Current Liabilities | 6.1B |
Non-Current Liabilities | 13.1B |
Long-Term Debt | 9.2B |
Other Non-Current Liabilities | 3.9B |
Earnings Waterfall
Merck KGaA
Revenue
|
21B
EUR
|
Cost of Revenue
|
-8.4B
EUR
|
Gross Profit
|
12.6B
EUR
|
Operating Expenses
|
-8.4B
EUR
|
Operating Income
|
4.2B
EUR
|
Other Expenses
|
-1.4B
EUR
|
Net Income
|
2.8B
EUR
|
Free Cash Flow Analysis
Merck KGaA
What is Free Cash Flow?
MRK Profitability Score
Profitability Due Diligence
Merck KGaA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Merck KGaA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
MRK Solvency Score
Solvency Due Diligence
Merck KGaA's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Merck KGaA's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRK Price Targets Summary
Merck KGaA
According to Wall Street analysts, the average 1-year price target for MRK is 185.58 EUR with a low forecast of 156.55 EUR and a high forecast of 220.5 EUR.
Shareholder Return
MRK Price
Merck KGaA
Average Annual Return | 22.94% |
Standard Deviation of Annual Returns | 32.51% |
Max Drawdown | -39% |
Market Capitalization | 63.8B EUR |
Shares Outstanding | 434 777 900 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. The company is headquartered in Darmstadt, Hessen and currently employs 60,334 full-time employees. The firm operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
Contact
IPO
Employees
Officers
The intrinsic value of one MRK stock under the Base Case scenario is 146.43 EUR.
Compared to the current market price of 146.75 EUR, Merck KGaA is Fairly Valued.